Meta-analysis of 15 clinical trials concerning the treatment of advanced ovarian cancer with PD-L1 inhibitors showed limited efficacy due to relatively low microsatellite instability and tumor mutational burden overall in EOCs. The gene discussed is CD274; the disease is neoplasm.